Pluri Therapeutics presented its scalable, automated cell expansion platform at a recent biotech symposium, highlighting production of high-density cell batches using microcarrier technology. The system is designed to reduce manufacturing costs and accelerate scale-up for the company’s regenerative medicine programs.

The Resbiomed wound-healing program progressed into preclinical proof-of-concept studies, where Pluri observed initial efficacy signals in early animal models. This milestone supports planning for regulatory filings and positions Resbiomed for IND-enabling activities later this year.